CanSino Biologics Inc.
OTC: CASBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Xue Feng Yu
- Employees
- 1,134
- Headquarters
- Tianjin, China
- IPO year
- 2020
- Market cap
- $999.0M
- Website
- http://www.cansinotech.com
Loading CASBF…
Loading profile data…Frequently asked questions about CASBF
What does CanSino Biologics Inc. (CASBF) do?
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vacci...
Where does CASBF trade?
CanSino Biologics Inc. (CASBF) trades on the Other OTC.
What sector is CASBF in?
CanSino Biologics Inc. (CASBF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of CanSino Biologics Inc.?
Xue Feng Yu is the chief executive officer of CanSino Biologics Inc. (CASBF).
Where is CanSino Biologics Inc. headquartered?
CanSino Biologics Inc. is headquartered in China.
Does CASBF pay a dividend?
CanSino Biologics Inc. (CASBF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CASBF go public?
CanSino Biologics Inc. (CASBF) completed its initial public offering in 2020.